Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants With Inflammatory Bowel Disease

NCT07652294 is registered in ClinicalTrials.gov with Spyre Therapeutics, Inc. as lead sponsor.

NCT NCT07652294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07652294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants With Inflammatory Bowel Disease
Lead sponsor
Spyre Therapeutics, Inc.
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
June 8, 2026
Completion date
January 3, 2030
Enrollment
645 (estimated)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, colitis, ulcerative, inflammatory bowel diseases, ulcerative colitis